Literature DB >> 8244095

Prospective multicentre study of risk factors associated with delayed healing of recurrent duodenal ulcers (RUDER). RUDER Study Group.

D Armstrong1, R Arnold, M Classen, M Fischer, H Goebell, A L Blum.   

Abstract

Risk factors for delayed duodenal ulcer healing during treatment with ranitidine (300 mg daily) were examined in a multicentre German study of 1923 patients with endoscopically proved, recurrent duodenal ulceration. Healing rates, per protocol, were 39.5% at two weeks, 70.9% at four weeks, and 93.2% at eight weeks. Prospective testing of five, predefined risk factors indicated that smoking (p = 0.0039) was associated with a decreased healing rate at two weeks. Frequent prior recurrence (p = 0.464), a heavy physical workload (p = 0.145), and psychological stress (p = 0.062) were not associated with a decreased healing rate and there were too few patients at risk to allow assessment of the effect of regular NSAID intake. Exploratory analysis identified prior slow healing, a large ulcer, multiple ulcers, and prior ulcer complications, in addition to smoking, as markers of slow healing. In the absence of these risk factors, the mean healing time was 3.3 weeks (95% confidence interval 3.0, 3.5), rising to 3.7 weeks (3.5, 3.9) for one, 4.4 weeks (4.1, 4.7) for two, and 5.1 weeks (4.5, 5.6) for three to five risk factors. Delayed duodenal ulcer healing is associated with multiple factors whose effect is cumulative; for patients with two or more of five easily identified risk factors, more than four weeks' treatment with a histamine H2 receptor antagonist is required to achieve ulcer healing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244095      PMCID: PMC1374534          DOI: 10.1136/gut.34.10.1319

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  The effect of stressful life situations on the healing of duodenal ulceration.

Authors:  J B Mason; M G Moshal; V Naidoo; L Schlemmer
Journal:  S Afr Med J       Date:  1981-11-07

2.  Sucralfate and cimetidine as single agents and in combination for treatment of active duodenal ulcers. A double-blind, placebo-controlled trial.

Authors:  G M Van Deventer; D Schneidman; J H Walsh
Journal:  Am J Med       Date:  1985-08-30       Impact factor: 4.965

3.  Refractory duodenal ulcer.

Authors:  K D Bardhan
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

4.  Cimetidine versus intensive antacid therapy for duodenal ulcer: a multicenter trial.

Authors:  A F Ippoliti; R A Sturdevant; J I Isenberg; M Binder; R Camacho; R Cano; C Cooney; M M Kline; R L Koretz; J H Meyer; I M Samloff; A D Schwabe; E A Strom; J E Valenzuela; R H Wintroub
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

5.  Ranitidine in duodenal ulcer: incidence of healing and effect of smoking.

Authors:  M G Korman; J Hansky; A C Merrett; G T Schmidt
Journal:  Dig Dis Sci       Date:  1982-08       Impact factor: 3.199

6.  Treatment of duodenal ulcer with pirenzepine and cimetidine.

Authors:  H Brunner; H Dittrich; P Kratochvil; G Brandstätter; E Hentschel; K Schütze; K H Tragl; H Kern; K Löffelmann; H Zeiler
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

7.  The factors determining success or failure of cimetidine treatment of peptic ulcer.

Authors:  M Hasan; W Sircus
Journal:  J Clin Gastroenterol       Date:  1981-09       Impact factor: 3.062

8.  Factors influencing healing of duodenal ulcer. Control of nocturnal secretion by H2 blockade and characteristics of patients who failed to heal.

Authors:  S K Lam; C L Lai; L N Lee; K H Fok; M M Ng; K F Siu
Journal:  Dig Dis Sci       Date:  1985-01       Impact factor: 3.199

9.  Bile reflux is increased in cigarette smokers.

Authors:  S A Müller-Lissner
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

10.  Factors affecting the healing rate of duodenal and pyloric ulcers with low-dose antacid treatment.

Authors:  S Massarrat; A Eisenmann
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

View more
  3 in total

Review 1.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 2.  pH, healing rate and symptom relief in acid-related diseases.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1996 Mar-Apr

3.  RUDER--a prospective, two-year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. RUDER Study Group.

Authors:  D Armstrong; R Arnold; M Classen; M Fischer; H Goebell; W Schepp; A L Blum
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.